Brokers Issue Forecasts for CRSP FY2027 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors on Tuesday, March 4th. Zacks Research analyst R. Department expects that the company will post earnings per share of ($4.62) for the year. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%.

Other research analysts have also issued research reports about the company. Evercore ISI upgraded CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price target for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Barclays lifted their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. JMP Securities reiterated a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Stifel Nicolaus dropped their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $73.11.

Remove Ads

CRISPR Therapeutics Stock Up 5.1 %

CRSP traded up $2.22 on Wednesday, hitting $45.53. The company had a trading volume of 1,884,937 shares, compared to its average volume of 2,267,393. The company has a market cap of $3.91 billion, a PE ratio of -10.42 and a beta of 1.77. CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $81.73. The business's fifty day simple moving average is $42.79 and its 200 day simple moving average is $45.77.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director John Greene acquired 7,000 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The shares were acquired at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the acquisition, the director now owns 7,000 shares of the company's stock, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Large investors have recently made changes to their positions in the stock. Wood Tarver Financial Group LLC purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at $30,000. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the third quarter valued at $40,000. Ameriflex Group Inc. acquired a new position in CRISPR Therapeutics during the fourth quarter valued at $36,000. Darwin Wealth Management LLC acquired a new position in CRISPR Therapeutics during the third quarter valued at $43,000. Finally, Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics during the fourth quarter valued at $39,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.